Market Place
Sourcing Support
ADC touts early Zynlonta results in marginal zone lymphoma
07 May 2024 //
FIERCE PHARMA
ADC Reports ZYNLONTA® Phase 2 Data In Marginal Zone Lymphoma
06 May 2024 //
GLOBENEWSWIRE
ADC Reports Q1 2024 Results, Provides Business Update
06 May 2024 //
GLOBENEWSWIRE
Overland ADCT Announces NMPA Accepts BLA & Grants Priority Review for ZYNLONTA
24 Jul 2023 //
GLOBENEWSWIRE
After seven deaths, ADC gets partial hold and decides to stop Zynlonta trial
22 Jul 2023 //
FIERCE PHARMA
ADC Therapeutics pauses enrollment in cancer drug trial after patient deaths
12 Jul 2023 //
REUTERS
ADC Announces LOTIS-2 Results Demonstrating Durable Responses of ZYNLONTA
09 Jun 2023 //
GLOBENEWSWIRE
Zynlonta® approved in the EU for the treatment of relapsed or refractory diffuse
21 Dec 2022 //
PRNEWSWIRE
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA
21 Dec 2022 //
BUSINESSWIRE
ADC Therapeutics Announces Abstracts to be Presented at Meeting of SOHO 2022
21 Sep 2022 //
BUSINESSWIRE
ADC Therapeutics & Sobi Announce ZYNLONTA Receives Positive CHMP Opinion
16 Sep 2022 //
BUSINESSWIRE
ADC to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
06 Sep 2022 //
BUSINESSWIRE
ADC Therapeutics Announces $175 million Senior Secured Term Loan
15 Aug 2022 //
BUSINESSWIRE
ADC Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Overland ADCT BioPharma Begins Dosing in China with ZYNLONTA in PIII trial
11 Jul 2022 //
BUSINESSWIRE
ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug
09 Jul 2022 //
BIOPHARMADIVE
ADC Tx Begins Dosing in PIb Trial of ZYNLONTA with Other Anti-cancer Agents
29 Jun 2022 //
BUSINESSWIRE
ADC Tx Announces Exclusive License with MTPC to Develop & Commercialize ZYNLONTA
18 Jan 2022 //
BIOSPACE
Durable Responses Observed With Loncastuximab Tesirine, Presented at SOHO
15 Sep 2021 //
FIRSTWORDPHARMA
ADC Therapeutics Presented ZYNLONTA Data at Conference on Malignant Lymphoma
18 Jun 2021 //
BUSINESSWIRE
ADC Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.
07 Jan 2021 //
BUSINESSWIRE
ADC Announces Updated Clinical Data on Lead ADC Loncastuximab Tesirine (Lonca)
07 Dec 2020 //
BUSINESSWIRE
ADC Announces Updated Clinical Data on Lead ADC Programs Loncastuximab
07 Dec 2020 //
BUSINESSWIRE
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at (NLA)
07 Dec 2020 //
GLOBENEWSWIRE
ADC gets a speedy FDA review for their DLBCL therapy
21 Nov 2020 //
ENDPTS
IPO, check: Now, ADC Therapeutics files for lonca approval
22 Sep 2020 //
FIERCE BIOTECH
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion
16 Jul 2020 //
BUSINESSWIRE
ADC Announces Maturing Data from Pivotal Ph2 Trial and Ph 1/2 Loncastuximab
11 Jun 2020 //
BUSINESSWIRE
ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine
05 Jun 2020 //
BUSINESSWIRE
ADC Announces Loncastuximab Tesirine (Lonca) Clinical Data
21 May 2020 //
BUSINESSWIRE
Led by BioNTech, six biotechs line up for October IPOs
27 Sep 2019 //
ENDPTS
Swiss biotech ADC Therapeutics guns for $150M IPO
09 Sep 2019 //
FIERCEBIOTECH
ADC Therapeutics taps Freenome to chart biomarkers for lead med
27 Aug 2019 //
FIERCE BIOTECH
ADC Therapeutics Rakes in $303 Million with Addition to its Series E
09 Jul 2019 //
BIOSPACE
ADC Therapeutics bumps up series E by $76M, preps lead drug for 2020 filing
11 Jun 2019 //
FIERCE BIOTECH
ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
05 Dec 2018 //
GLOBENEWSWIRE
ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602
27 Nov 2018 //
GLOBENEWSWIRE
ADC Therapeutics Secures Additional Equity Round Investment
15 Nov 2018 //
PRESS RELEASE
PCI and ADC Bio add to manufacturing; recalls up
15 Nov 2018 //
FIERCE PHARMA
After mega-round investment, ADC Therapeutics cans PhI trial in HER2
26 Apr 2018 //
ENDPTS
ADC Bio signs agreement with sector specialists WHP
06 Dec 2017 //
BIOSPECTRUM
